TABLE 3.
Crude and adjusted HRs and ORs associated with baseline serum CC16 for incident airflow limitation in TESAOD (Table 3a) and in the replication population of ECRHS-Sp (Table 3b). The highest CC16 tertile is the reference group.
| a | Hazard Ratios for incident airflow limitation N subjects who developed airflow limitation/total N subjects (251/958)ˆ | Hazard Ratios for incident stage 2 airflow limitation N subjects who developed stage 2 airflow limitation/total N subjects (106/958)ˆ | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Crude HR (95% CI) P value |
Adj* HR (95% CI) P value |
Adj** HR (95% CI) P value |
Crude HR (95% CI) P value |
Adj* HR (95% CI) P value |
Adj** HR (95% CI) P value |
|
| Effect associated with baseline CC16 tertiles | ||||||
| HIGH | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| MEDIUM | 1.09 (0.79 – 1.49) p = 0.613 |
1.17 (0.86 – 1.60) p = 0.325 |
1.15 (0.84 – 1.57) p = 0.376 |
1.53 (0.89 – 2.60) p = 0.121 |
1.65 (0.97 – 2.82) p = 0.067 |
1.71 (1.00 – 2.93) p = 0.051 |
| LOW | 1.45 (1.07 – 1.96) p = 0.017 |
1.15 (0.84 – 1.58) p = 0.387 |
1.10 (0.79 – 1.51) p = 0.573 |
2.36 (1.44 – 3.88) p = 0.0007 |
1.82 (1.08 – 3.07) p = 0.024 |
1.81 (1.06 – 3.09) p = 0.029 |
| P value for trend | 0.017 | 0.403 | 0.596 | 0.0005 | 0.026 | 0.032 |
|
| ||||||
| Effect associated with 1-SD decrease in CC16 | 1.17 (1.02 – 1.33) p = 0.022 |
1.09 (0.93 – 1.27) p = 0.284 |
1.06 (0.91 – 1.23) p = 0.458 |
1.37 (1.16 – 1.61) p = 0.0002 |
1.29 (1.04 – 1.59) p = 0.019 |
1.27 (1.03 – 1.56) p = 0.026 |
|
| ||||||
| Harrell’s C statistics (model with CC16 tertiles) | 0.55 | 0.73 | 0.81 | 0.60 | 0.79 | 0.83 |
| b | Odds Ratios for incident airflow limitation N subjects who developed airflow limitation/total N subjects (70/495)ˆ | Odds Ratios for incident stage 2 airflow limitation N subjects who developed stage 2 airflow limitation/total N subjects (28/495)ˆ | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| Crude OR (95% CI) P value |
Adj* OR (95% CI) P value |
Adj** OR (95% CI) P value |
Crude OR (95% CI) P value |
Adj* OR (95% CI) P value |
Adj** OR (95% CI) P value |
|
| Effect associated with baseline CC16 tertiles | ||||||
| HIGH | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| MEDIUM | 1.53 (0.76 – 3.06) p = 0.232 |
1.47 (0.72 – 3.02) p = 0.289 |
1.37 (0.56 – 3.36) p = 0.488 |
2.04 (0.60 – 6.91) p = 0.253 |
1.89 (0.53 – 6.66) p = 0.324 |
1.80 (0.46 – 7.02) p = 0.397 |
| LOW | 2.41 (1.25 – 4.64) p = 0.0083 |
2.14 (1.06 – 4.30) p = 0.033 |
2.12 (0.89 – 5.05) p = 0.091 |
4.18 (1.37 – 12.8) p = 0.012 |
3.35 (1.02 – 10.9) p = 0.045 |
3.06 (0.84 – 11.2) p = 0.090 |
| P value for trend | 0.0070 | 0.032 | 0.085 | 0.0072 | 0.036 | 0.079 |
|
| ||||||
| Effect associated with 1-SD decrease in CC16 | 1.47 (1.17 – 1.85) p = 0.0011 |
1.39 (1.08 – 1.80) p = 0.012 |
1.38 (1.00 – 1.92) p = 0.051 |
1.75 (1.27 – 2.40) p = 0.0005 |
1.64 (1.13 – 2.40) p = 0.010 |
1.53 (1.00 – 2.34) p = 0.049 |
|
| ||||||
| AUC (model with CC16 tertiles) | 0.60 | 0.70 | 0.92 | 0.65 | 0.81 | 0.91 |
adjusted for sex, age, smoking status and intensity, pack-years, and asthma at baseline
adjusted for sex, age, smoking status and intensity, pack-years, asthma, and FEV1/FVC at baseline. These covariates were included because they are known to affect the risk for COPD.
Of the 960 TESAOD participants, 2 had missing smoking or asthma information and were excluded from analyses
adjusted for center, sample type (random versus enriched), sex, age, smoking status and intensity, pack-years, and asthma at baseline
adjusted for center, sample type (random versus enriched), sex, age, smoking status and intensity, pack-years, asthma, and FEV1/FVC at baseline
Of the 514 ECRHS-Sp participants, 19 had missing smoking status and/or intensity information and were excluded from analyses